OTCMKTS:INTI Inhibitor Therapeutics (INTI) Stock Price, News & Analysis → Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad) Free INTI Stock Alerts $0.09 +0.03 (+53.76%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.09▼$0.0950-Day Range$0.05▼$0.0952-Week Range$0.01▼$0.30Volume250 shsAverage Volume14,426 shsMarket Capitalization$14.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Inhibitor Therapeutics alerts: Email Address Ad GoldenCrest MetalsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.Learn More Now About Inhibitor Therapeutics Stock (OTCMKTS:INTI)Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.Read More INTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INTI Stock News HeadlinesApril 24, 2024 | finance.yahoo.comHDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsightApril 22, 2024 | finance.yahoo.comEGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsightApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.April 15, 2024 | finance.yahoo.comCyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Research Report 2024: Drugs in Development, Therapeutics Scenario and Growth ProspectsApril 8, 2024 | msn.comSaruparib demonstrates early efficacy in breast cancers with DNA repair defects in Phase I/II trialApril 3, 2024 | finance.yahoo.comWatchmaker Genomics Announces Launch of Cost-effective RNase Inhibitor for Single-cell, Single-nuclei, and Pathogen Detection ApplicationsMarch 14, 2024 | finance.yahoo.comJanus Kinase (JAK) Inhibitor Market Forecast 2024-2034: Analyzes Trends Likely to Shape Future OpportunitiesMarch 14, 2024 | finance.yahoo.comExploring the FcRn Inhibitor Market Landscape, 2024: Market Insights, Pipeline Analysis, Expert Perspectives, and Future Trends to 2034April 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.January 10, 2024 | seekingalpha.comiTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must WatchJanuary 10, 2024 | tmcnet.comVYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of VitiligoDecember 19, 2023 | finance.yahoo.comIntroducing Inhibitor Therapeutics, Inc. New Scientific Advisory BoardDecember 13, 2023 | finance.yahoo.comInhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins UniversityDecember 4, 2023 | tmcnet.comInhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001ProNovember 14, 2023 | markets.businessinsider.comInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period ActivityNovember 7, 2023 | finance.yahoo.comCardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023October 16, 2023 | businesswire.comAntiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer TherapeuticsSeptember 5, 2023 | benzinga.comNykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical CancerMay 18, 2023 | finanznachrichten.deTrueline Therapeutics Inc.: Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810May 18, 2023 | businesswire.comTrueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810May 17, 2023 | marketwatch.comCorrosion Inhibitor for Oil and Gas Market | Worldwide Industry Trends 2023-2030May 17, 2023 | marketwatch.comWax Inhibitor Market 2023 Fastest Growing Industry in Advanced Material Market by 2030April 20, 2023 | wsj.comInhibitor Therapeutics Inc.April 4, 2023 | msn.comOncternal Therapeutics Announces Strategic Reprioritization, Stops Two Zilovertamab StudiesApril 4, 2023 | uk.finance.yahoo.comiOmx Therapeutics Announces Dosing of First Patient with SIK Inhibitor OMX-0407 in Phase I Clinical TrialMarch 31, 2023 | marketwatch.com2023-2029 Medical FLT3 Inhibitor Market Share and Growth Insights | Latest Research ReportMarch 25, 2023 | marketwatch.comNorepinephrine Reuptake Inhibitor Market Share by 2031See More Headlines Receive INTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today4/24/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:INTI CUSIPN/A CIK1042418 Webwww.inhibitortx.com Phone(888) 841-6811Fax813-527-0500Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.51% Return on Assets-30.61% Debt Debt-to-Equity RatioN/A Current Ratio13.46 Quick Ratio13.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book2.86Miscellaneous Outstanding Shares171,970,000Free Float164,057,000Market Cap$14.76 million OptionableNot Optionable Beta-0.84 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Francis E. O'Donnell Jr. (Age 74)M.D., Founder, Executive Chairman & CEO Comp: $600kMr. James A. McNulty CPA (Age 74)Interim CFO, Treasurer & Secretary Comp: $205.4kKey CompetitorsAeterna ZentarisNASDAQ:AEZSGalera TherapeuticsNASDAQ:GRTXAlterity TherapeuticsNASDAQ:ATHEMoleculin BiotechNASDAQ:MBRXAkari TherapeuticsNASDAQ:AKTXView All Competitors INTI Stock Analysis - Frequently Asked Questions How have INTI shares performed in 2024? Inhibitor Therapeutics' stock was trading at $0.0920 at the start of the year. Since then, INTI stock has decreased by 6.7% and is now trading at $0.0858. View the best growth stocks for 2024 here. Are investors shorting Inhibitor Therapeutics? Inhibitor Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 500 shares, an increase of 400.0% from the March 15th total of 100 shares. Based on an average trading volume of 37,200 shares, the short-interest ratio is currently 0.0 days. View Inhibitor Therapeutics' Short Interest. When is Inhibitor Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our INTI earnings forecast. How were Inhibitor Therapeutics' earnings last quarter? Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) announced its quarterly earnings results on Friday, March, 29th. The company reported ($0.01) earnings per share for the quarter. How do I buy shares of Inhibitor Therapeutics? Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:INTI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
